Overcoming Tumor Resistance: Targeting Stromal Components in Cancer Treatment

The word “cancer” is still frightening to hear, despite the great improvement in cancer treatments and outcomes in recent years. Causing more than 10 million deaths annually, cancer stands as the second leading cause of death globally. Cancer is a generic term for many diseases that may impact any body part. While global oncology treatment strategies have improved, there has been a rise in cancer cases as a whole. Currently, most antitumor therapies target and eliminate cancer cells, and are not designed to affect the tumor stroma directly. Tumor recurrence can result from the interactions of the tumor stroma with both cancer cells and anticancer therapies. This research paper explores the relationship between cancer cells and the tumor stroma by evaluating the effectiveness of current cancer therapies alongside stromal-targeted treatments. The stroma promotes tumor growth through its interactions with the cancer cells, leading to resistance from traditional therapies. The tumor stroma can lead to reduced effectiveness of cancer therapy strategies through its various components. Therefore, proposed solutions should not only target cancer cells but aim to disrupt the stroma’s support or develop it into a tumor-repressive state. Addressing both cancer cells and the stromal environment may improve treatment effectiveness and reduce the likelihood of tumor relapse.